Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers.

Journal of clinical pharmacology - 1 Apr 2015

Joseph David, Rose Peter, Strelkowa Natalja, Schultz Armin, Garcia Jeanette, Elgadi Mabrouk, Huang Fenglei

Abstract excerpt

Faldaprevir is a potent hepatitis C virus (HCV) NS3/4A protease inhibitor and an inhibitor of UDP-glucuronosyltransferase-1A1 (UGT1A1), which is involved in raltegravir clearance. Raltegravir, an HIV integrase inhibitor, may be used in combination with HCV treatment in HCV/HIV co-infected patients. In this open-label, 2-period, fixed-sequence study, 24 healthy volunteers (12 males) received faldaprevir 240 mg and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoisobutyric Acids
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Healthy Volunteers

Share to HIV Integrase Inhibitors

Share to Protease Inhibitors

Share to Quinolines

Share to Raltegravir Potassium

Share to Thiazoles

Source

Identifiers

PMID: 25352040
DOI: 10.1002/jcph.418

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers.PMID 25352040Read ↗

Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV.Semantic proximity Read ↗

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.Semantic proximity Read ↗

Pharmacokinetics and pharmacodynamics of sofosbuvir and ledipasvir for the treatment of hepatitis C.Semantic proximity Read ↗

SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.Semantic proximity Read ↗

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy SubjectsSemantic proximity Read ↗

A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.Semantic proximity Read ↗

Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis.Semantic proximity Read ↗

Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.Semantic proximity Read ↗

Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.Semantic proximity Read ↗

Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.Semantic proximity Read ↗

Characterizing complex and competing drug-drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine.Semantic proximity Read ↗

Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.